Ubrogepant (Ubrelvy) (Ubrogepant) for Personal Injury
Drug Class: CGRP Receptor Antagonist (Gepant) — Acute Treatment
Common Uses
- Acute treatment of migraine attacks with or without aura
- Post-traumatic migraine following car accidents or head trauma
- Acute migraine rescue alongside a daily preventive medication
- Migraine treatment in patients who cannot tolerate triptans
How It Helps in Personal Injury Cases
Ubrogepant (Ubrelvy) is an acute migraine rescue medication commonly prescribed for personal injury patients who experience breakthrough migraine attacks despite preventive therapy. In PI cases, it is often paired with a daily CGRP preventive like atogepant (Qulipta), with ubrogepant addressing individual attacks as they occur. Its as-needed use creates prescription records that document individual migraine episodes.
Ubrogepant blocks the CGRP receptor in the trigeminal nervous system at the time of a migraine attack, interrupting the neurogenic cascade that produces headache, nausea, and light/sound sensitivity. Unlike triptans, which constrict blood vessels, ubrogepant has no vasoconstrictive mechanism — making it safe for patients with cardiovascular risk factors who would otherwise have limited acute migraine options.
Ubrogepant (Ubrelvy) for Acute Migraine After a Personal Injury
Ubrogepant, sold as Ubrelvy, is an oral tablet taken at the onset of a migraine attack to provide acute relief. It is FDA-approved for the acute treatment of migraine with or without aura.
How It Works
Ubrogepant blocks the CGRP receptor, stopping the migraine cascade before it fully develops. Unlike triptans, it does not constrict blood vessels — making it an option for patients with cardiovascular conditions who cannot take traditional triptan medications.
Dosing
- 50mg or 100mg tablet taken at migraine onset
- A second dose of the same strength may be taken 2 hours later if needed
- Maximum 2 doses per day
Role in PI Treatment
Post-traumatic migraine patients who experience breakthrough attacks despite daily preventive therapy need an effective acute rescue medication. Ubrogepant fills this role — it is specifically designed to treat individual attacks as they occur.
In personal injury cases, ubrogepant is commonly paired with a daily CGRP preventive:
- Atogepant (Qulipta) — daily for prevention
- Ubrogepant (Ubrelvy) — as needed for acute attacks
This two-medication approach is the standard of care for frequent migraine and creates documented records of both preventive and acute neurological treatment.
Clinical Evidence
The ACHIEVE I and ACHIEVE II trials demonstrated statistically significant pain freedom at 2 hours versus placebo (19.2% vs 11.9% at 100mg in ACHIEVE I) and meaningful reduction in the patient's most bothersome symptom.
Accessing Ubrogepant Through LienScripts
Ubrogepant is brand-name only. LienScripts provides pharmacy lien coverage at $0 upfront cost for qualified personal injury patients.
Dosage Forms
- Tablet 50mg
- Tablet 100mg
- Second dose (same strength) may be taken 2 hours after the first if insufficient response
Common Side Effects
- Nausea (most common)
- Somnolence (drowsiness)
- Dry mouth
- Fatigue
Frequently Asked Questions
When is ubrogepant taken?
Ubrogepant is taken at the onset of a migraine attack. A second dose may be taken 2 hours later if needed. It is not a preventive medication — it does not prevent future attacks. Patients who need both acute treatment and prevention typically also take a daily preventive like atogepant (Qulipta).
Is ubrogepant safer than triptans for patients with heart conditions?
Yes. Ubrogepant does not constrict blood vessels, which is the mechanism triptans use that makes them potentially problematic in patients with cardiovascular disease, uncontrolled hypertension, or history of stroke. Ubrogepant is an option for patients who cannot take triptans for cardiovascular reasons.
Can ubrogepant be used with preventive CGRP medications?
Yes. Ubrogepant for acute attacks is commonly used alongside a daily CGRP preventive like atogepant (Qulipta). The preventive reduces attack frequency; ubrogepant treats breakthrough attacks that still occur. This combination approach is standard neurological care for migraine.
Is there a generic version of Ubrelvy?
No. Ubrogepant is available only as Ubrelvy. There is no generic alternative.